CSChao Shang

Chao Shang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chao Shang has a total of 136 co-authors. Here are the top co-authors by number of shared publications:

  • Xiao Li

    Changchun Veterinary Research Institute Chinese Academy of Agricultural Sciences Changchun China

    11 shared publications
  • Ningyi Jin

    Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China

    5 shared publications
  • Dapeng Li

    Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China

    4 shared publications
  • Xiaoyang Yu

    Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China

    4 shared publications
  • Yiquan Li

    College of Integrative Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China

    4 shared publications
  • Chenchen Ge

    Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China

    3 shared publications

Latest Publications

  • Open Access

    A Dual‐Membrane Biomimetic Nanoplatform Enables Triple‐Modal Therapy Against SARS‐CoV‐2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi

    by Hui Li, Bohan Zhang, Chao Shang, Yi Li, Te Zhao, Shengya Liu, Dan Liu, Junwei Che, Cuiling Zhang, Pinghui Wu, et al.

    The persistent evolution of SARS‐CoV‐2 and the concomitant risk of life‐threatening hyperinflammation, such as cytokine storm syndrome, underscore the urgent need for therapeutic strategies that simultaneously target viral replication and dysregulated host immunity. Herein, we describe a dual‐membrane biomimetic nanoplatform, designated [A&T]MLN, comprising siRNA‐loaded lipid nanoparticles with a hybrid membrane derived from ACE2‐overexpressing HEK293T cells and THP‐1 macrophages. This design integrates a high‐density viral decoy based on ACE2 with the inherent immunomodulatory capacity of macrophage membranes. [A&T]MLN demonstrates broad‐spectrum and potent neutralization of diverse SARS‐CoV‐2 variants by competitively blocking viral entry, while actively scavenging key inflammatory cytokines (including IL‐6, IL‐1β, and TNF‐α) via membrane‐displayed receptors. In a murine model of acute lung injury that recapitulates COVID‐19 immunopathology, [A&T]MLN treatment significantly attenuated pulmonary inflammation and tissue damage. Additionally, the platform enabled efficient cytosolic delivery of siRNA, establishing a third modality for intracellular suppression of viral gene expression. Collectively, [A&T]MLN represents a complementary triple‐modal therapy that simultaneously addresses viral entry, intracellular replication, and hyperinflammation (the core interconnected pathologies of severe COVID‐19), offering a versatile and adaptive strategy against evolving SARS‐CoV‐2 variants and related inflammatory syndromes.

  • Open Access

    Ad-VT oncolytic adenovirus suppresses bladder cancer via cAMP-dependent AMPK-Raptor activation and G2/M arrest

    by Dapeng Li, Jing Lu, Ran Zhu, Xianyan Sun, Cuiling Zhang, Mingzhe Sun, Chengyuan Ma, Chao Shang, Xiao Li


  • Open Access

    VPS34 inhibition as a host-targeting anti-coronaviral strategy: Rational design of YBM with optimized pharmacokinetic parameters

    by Chenchen Ge, Zihao Wang, Zhiwei Zhao, Xiaoyu Zhang, Xiaoyang Yu, Minghua Chen, Kai Liu, Lisen Lin, Dapeng Li, Ningyi Jin, et al.


  • Open Access

    Transmissibility of Clade IIb Monkeypox Virus in Young Rabbits

    by Zhaoliang Chen, Lei Zhang, Linzhi Li, Mingjie Shao, Mingda Zhang, Zongzheng Zhao, Chao Shang, Zirui Liu, Juxiang Liu, Zhendong Guo

    The monkeypox virus (MPXV) has spread globally, posing a severe challenge to global public health. This study systematically evaluated the aerosol shedding dynamics of the epidemic Clade IIb MPXV strain in infected young rabbits, along with its direct contact and airborne transmission potential among them. We found that young rabbits could be experimentally infected with MPXV, exhibiting distinct pathogenic features and viral shedding patterns. Young rabbits infected with MPXV shed the virus through nasal secretions and exhaled aerosols, peaking at 7 dpi. In total, 89–95.8% of virus-laden respiratory particles had a diameter ≥4.7 μm. Notably, MPXV can be efficiently shed and transferred among young rabbits through direct contact and airborne routes. The nasal secretions and exhaled virus particles from donor rabbits can be contacted or inhaled by recipient rabbits. Large amounts of viral DNA were detected in the nasal wash of rabbits exposed to contact or airborne exposure. Furthermore, virus particles invade the lungs, causing pathological changes and disseminating them to multiple organs. However, no infectious virus was successfully recovered from these recipient rabbits, as their exposed or inhaled MPXV dose might have been below the MPXV’s minimum infectious dose for young rabbits. These findings indicate that although the airborne transmissibility of the current MPXV strain is relatively limited, inhalation of viral particles following airborne exposure can still result in bodily damage. Continuous monitoring of MPXV transmissibility and mutation evolution is imperative to prevent efficient respiratory aerosol transmission, which guides global monkeypox prevention and control strategies.

  • Open Access

    Avian Influenza Surveillance Among Migratory Birds, Poultry, and Humans Around Nansi Lake, China, 2021–2024

    by Sheng Zhang, Yu-Min Liang, Dong-Mei Wang, Chao Shang, Wang-Qian Wei, Xin-Jing Zhao, Li-Bo Li, Wen-Guo Jiang, Bao-Jin Guo, Bo-Yan Jiao, et al.

    Avian influenza A viruses (AIVs) pose a significant pandemic threat due to their cross-species transmission potential. However, AIV surveillance at the critical “migratory birds–poultry-exposed population” interface remains limited. Between 2021 and 2024, we implemented a prospective One Health surveillance program around Nansi Lake, monitoring AIVs in migratory birds, poultry, and environmental samples, as well as serological investigations against representative AIVs among migratory birds or poultry-exposed subjects. AIVs were detected in 2.1% (30/1417) of migratory bird samples and 10.2% (100/978) of poultry samples. Among these, we identified ten highly pathogenic avian influenza (HPAI) H5 subtype viruses, one HPAI H7N9 virus, and five low pathogenic avian influenza (LPAI) H9N2 viruses. Phylogenetic analysis revealed evidence of frequent genomic reassortment events involving H5 subtype viruses among migratory birds, poultry, and humans. Serological investigation also suggested that both migratory birds and the poultry-exposed population had a higher risk of getting AIV infection than the general control population, especially against the H9N2 virus. Our study emphasizes the importance of strengthening continuous prospective surveillance of AIVs among migratory birds, poultry, and their exposed individuals to prevent and control potential outbreaks.


  • Open Access

    Multiple gene-deletion vaccinia virus Tiantan strain against mpox

    by Yilong Zhu, Dapeng Li, Renshuang Zhao, Minghua Chen, Yue Li, Xia Yang, Hongyue Mao, Xiao Li, Yiquan Li, Chao Shang, et al.

    Monkeypox virus (MPXV) is an important zoonotic pathogenic virus, which poses serious threats to public health. MPXV infection can be prevented by immunization against the variola virus. Because of the safety risks and side effects of vaccination with live vaccinia virus (VACV) strain Tian Tan (VTT), we constructed two gene-deleted VTT recombinants (TTVAC7 and TTVC5). The immunogenicity and protective effects of the gene-deleted VTT vaccine were assessed using BALB/C mice challenged with VTT and New Zealand rabbits challenged with MPXV. The results demonstrated strong humoral and cellular immune responses. The VTT-specific and neutralizing antibody titers, specific T cell levels, and degree of dendritic cell maturation of the mice, in addition to the MPXV neutralizing antibody titers and IFN-γ, IL-6, and TNF-α levels of the rabbits were markedly higher in the groups immunized with TTVAC7 and TTVC5 than the control groups (p < 0.05). Moreover, immunization with TTVAC7 and TTVC5 reduced morbidities caused by VACV and MPXV infection. The weight change, lung histological score, and residual virus of the mouse model (p < 0.05). Similarly, the temperature change, pock number, lung histological score, and residual virus of the rabbit model were significantly reduced in the groups immunized with TTVAC7 and TTVC5 (p < 0.05). Collectively, these results demonstrate that TTVAC7 and TTVC5 may be used as potential live attenuated vaccines against MPXV infection.


  • Open Access

    SARS-CoV-2 NSP6 reduces autophagosome size and affects viral replication via sigma-1 receptor

    by Cuiling Zhang, Qiwei Jiang, Zirui Liu, Nan Li, Zhuo Hao, Gaojie Song, Dapeng Li, Minghua Chen, Lisen Lin, Yan Liu, et al.

    Autophagy is a cellular self-defense mechanism by which cells can kill invading pathogenic microorganisms and increase the presentation of components of pathogens as antigens. Contrarily, pathogens can utilize autophagy to enhance their own replication. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) NSP6 can interact with ATPase proton pump component to inhibit lysosomal acidification, which was implicated in the autophagy process. However, research on how SARS-CoV-2 NSP6 affected autophagy, and its impact on virus replication is still lacking. Coronavirus NSP6 has been reported to promote coronavirus replication by limiting autophagosome expansion. However, this finding has not been confirmed in coronavirus disease 2019 (COVID-19). We investigated the effect of NSP6 protein on autophagosomes in different mutant strains of SARS-CoV-2 and revealed that the size of autophagosomes was reduced by NSP6 of the wild-type and Delta variant of SARS-CoV-2. In addition, we found that SARS-CoV-2 NSP6 localized to the lysosome and had an inhibitory effect on the binding of autophagosomes to the lysosome, which blocked the autophagy flux; this may be related to endoplasmic reticulum (ER)-related pathways. We also found that sigma-1 receptor (SIGMAR1) knock out (KO) reversed NSP6-induced autophagosome abnormality and resisted SARS-CoV-2 infection, which responds to the fact that SIGMAR1 is likely to be used as a potential target for the treatment of SARS-CoV-2 infection. In summary, we have provided a preliminary explanation of the effects on autophagy of the SARS-CoV-2 NSP6 protein from the pre-autophagic and late stages, and also found that SIGMAR1 is likely to be used as a potential target for SARS-CoV-2 therapy to develop relevant drugs. IMPORTANCE: We have provided a preliminary explanation of the effects on autophagy of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) non-structure protein 6 from the pre-autophagic and late stages, and also found that sigma-1 receptor is likely to be used as a potential target for SARS-CoV-2 therapy to develop relevant drugs.